Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PASI 75 comparisons

PASI 75 comparisons

PASI 75 comparisons
Based on Phase III data announced last week for plaque psoriasis, Johnson & Johnson's ustekinumab (CNTO 1275) looks to be as good as the two best biologics - Humira and Remicade - in terms of efficacy and better in terms of dosing. JNJ's antibody targeting interleukin-12 (IL-12) and IL-23 met

Read the full 561 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers